Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Sep:118:142-148.
doi: 10.1016/j.ejca.2019.06.009. Epub 2019 Jul 20.

Ten-year results of the Multicentric Italian Lung Detection trial demonstrate the safety and efficacy of biennial lung cancer screening

U Pastorino  1 , N Sverzellati  2 , S Sestini  3 , M Silva  2 , F Sabia  3 , M Boeri  4 , A Cantarutti  5 , G Sozzi  4 , G Corrao  5 , A Marchianò  6
Affiliations
Randomized Controlled Trial

Ten-year results of the Multicentric Italian Lung Detection trial demonstrate the safety and efficacy of biennial lung cancer screening

U Pastorino et al. Eur J Cancer. 2019 Sep.

Abstract

Background: The Multicentric Italian Lung Detection (MILD) trial demonstrated that prolonged low-dose computed tomography (LDCT) screening could achieve a 39% reduction in lung cancer (LC) mortality. We have here evaluated the long-term results of annual vs. biennial LDCT and the impact of screening intensity on overall and LC-specific mortality at 10 years.

Patients and methods: Between 2005 and 2018, the MILD trial prospectively randomised the 2376 screening arm participants to annual (n = 1190) or biennial (n = 1186) LDCT, for a median screening period of 6.2 years and 23,083 person-years of follow-up. The primary outcomes were 10-year overall and LC-specific mortality, and the secondary end-points were the frequency of advanced-stage and interval LCs.

Results: The biennial LDCT arm showed a similar overall mortality (hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.57-1.12) and LC-specific mortality at 10 years (HR 1.10, 95% CI 0.59-2.05), as compared with the annual LDCT arm. Biennial screening saved 44% of follow-up LDCTs in subjects with negative baseline LDCT, and 38% of LDCTs in all participants, with no increase in the occurrence of stage II-IV or interval LCs.

Conclusions: The MILD trial provides original evidence that prolonged screening beyond five years with biennial LDCT can achieve an LC mortality reduction comparable to annual LDCT, in subjects with a negative baseline examination.

Keywords: Biennial; Computed tomography; Early detection; Interval; LDCT; Lung cancer; Mortality; Overdiagnosis; Screening.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement

None declared.

Figures

Figure 1
Figure 1
(A) Lung cancer incidence at 10 years by randomization arm. (B) Overall mortality at 10 years by randomization arm.
Figure 2
Figure 2
(A) Lung cancer mortality at 10 years by randomization arm. (B) Other causes mortality at 10 years by randomization arm.
See this image and copyright information in PMC

References

    1. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409. doi: 10.1056/NEJMoa1102873. - DOI - PMC - PubMed
    1. Infante M, Cavuto S, Lutman FR, Passera E, Chiarenza M, Chiesa G, et al.; DANTE Study Group. Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography. Am J Respir Crit Care Med. 2015;191:1166–75. doi: 10.1164/rccm.201408-1475OC. - DOI - PubMed
    1. Wille MM, Dirksen A, Ashraf H, Saghir Z, Bach KS, Brodersen J, et al. Results of the Randomized Danish Lung Cancer Screening Trial with Focus on High-Risk Profiling. Am J Respir Crit Care Med. 2016;193:542–51. doi: 10.1164/rccm.201505-10400C. - DOI - PubMed
    1. Pastorino U, Rossi M, Rosato V, Marchianò A, Sverzellati N, Morosi C, et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev. 2012;21:308–15. doi: 10.1097/CEJ.0b013e328351e1b6. - DOI - PubMed
    1. Pastorino U, Silva M, Sestini S, Sabia F, Boeri M, Cantarutti A, et al. Prolonged Lung Cancer Screening Reduced 10-year Mortality in the MILD Trial. Ann Oncol. 2019. doi: 10.1093/annonc/mdz117. - DOI - PMC - PubMed

Publication types